• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Tempus, Cleveland Clinic collaborate on personalized medicine initiative

Tempus, Cleveland Clinic collaborate on personalized medicine initiative

September 18, 2017
CenterWatch Staff

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Cleveland Clinic Taussig Cancer Institute will collaborate on a precision medicine initiative aimed at improving outcomes for patients diagnosed with cancer.

As part of the research collaboration spanning multiple cancer subtypes, Tempus will provide molecular sequencing and analysis for patients enrolled in a precision oncology clinical study at Taussig Cancer Institute. This study is enrolling patients with advanced (metastatic or incurable) cancer who are running out of standard treatment options. The goal is to identify targeted therapies and/or clinical trials that a patient may be a good candidate for and to uncover patterns of clinical significance leading to more effective, personalized treatments.

“We are committed to supporting our clinicians and scientists in using complex information and advanced technology to care for our patients. Incorporating advanced genomic data may enhance our ability to analyze vast amounts of clinical and molecular data, as we seek to improve the treatment options for our patients,” said Dr. Brian J. Bolwell, chairman of Cleveland Clinic Taussig Cancer Institute, which is both an NCI-designated comprehensive cancer center and a top-ranked national provider of advanced cancer care to thousands of patients diagnosed with cancer every year.

“We are pleased to collaborate with Cleveland Clinic, a world-renowned hospital that has built its reputation by providing high quality care to its patients, and we’re thrilled to be supporting its efforts to further incorporate genomic data into their clinical and research practice,” said Eric Lefkofsky, Founder and CEO of Tempus.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing